Last updated: February 23, 2026
What Is NDC 00713-0637?
NDC 00713-0637 identifies a specific pharmaceutical product. Based on the dataset, this NDC corresponds to Rivaroxaban 15 mg tablets, marketed under the brand name Xarelto by Johnson & Johnson. It is an anticoagulant used to prevent stroke and treat deep vein thrombosis (DVT) and pulmonary embolism (PE).
Current Market Landscape
Market Size and Demand
- The global anticoagulant market was valued at approximately USD 14 billion in 2022.
- CAGR (Compound Annual Growth Rate): 7%, projected to reach USD 22 billion by 2028 [1].
- The US accounts for around 40% of the global demand, driven by aging populations and increasing cardiovascular disease prevalence.
- Rivaroxaban’s market share among oral anticoagulants is estimated at 45% within the US [2].
Competitive Environment
Key competitors include:
- Apixaban (Eliquis)
- Dabigatran (Pradaxa)
- Edoxaban (Savaysa)
Market entries have been increasingly driven by cost advantages and novel formulations.
Distribution Channels
Pharmacies (retail and hospital), mail-order services, and specialty clinics comprise major channels. Pricing negotiations often occur during formulary reviews by payers.
Regulatory and Reimbursement Trends
- FDA approval for Xarelto is in place since 2011.
- CMS (Centers for Medicare & Medicaid Services) and private insurers increasingly favor cost-effective anticoagulants.
- Discount programs and patient assistance initiatives impact net prices.
Price Data and Cost Trends
Current Pricing (as of Q1 2023)
| Parameter |
Estimation |
| Average Wholesale Price (AWP) |
USD 5.25 per tablet (15 mg dose) |
| Average Selling Price (ASP) |
USD 4.75 per tablet |
| Medicaid Reimbursement |
USD 3.80 per tablet |
| Commercial Insurance Reimbursement |
USD 4.20 per tablet |
Price Dynamics
- Slight decrease (~5%) in wholesale prices over 2022 due to increased generic competition.
- Payer discounts of 10-15% on list prices are common.
- Impact of biosimilars or improved formulations could affect prices further.
Future Price Projections (Next 3-5 Years)
| Year |
Projected Wholesale Price (USD) |
Notes |
| 2024 |
USD 4.80 - 5.10 |
Slight decrease expected with increased market penetration of generics and biosimilars. |
| 2025 |
USD 4.70 - 5.00 |
Continued erosion of list price due to competitive pressure. |
| 2026 |
USD 4.60 - 4.90 |
Introduction of potential biosimilar competitors; payer negotiations intensify. |
| 2027 |
USD 4.50 - 4.80 |
Memorial stabilization; price pressure persists from biosimilar entries. |
Key Market Drivers
- Patent expiration and biosimilar entries will prompt price reductions.
- Healthcare policy shifts toward value-based care influence reimbursement rates.
- Generic molecule approvals by the FDA impact brand pricing strategies.
- Physician prescribing habits are influenced by cost, efficacy, and safety profile.
Strategic Implications
- For manufacturers, expanding indications and biosimilar development are critical.
- Investors should monitor patent expiry timelines, notably in 2026.
- Payers will seek pharmacy benefit management (PBM) discounts, further reducing net prices.
Key Takeaways
- NDC 00713-0637 (Xarelto 15 mg) operates within a high-growth anticoagulant market.
- Market share is competitive, with approximately 45% among oral anticoagulants.
- Wholesale prices are approximately USD 5.25 per tablet, trending downward.
- Price projections suggest stable to slightly declining prices over the next five years, driven by biosimilar competition and procurement negotiations.
- Regulatory and reimbursement policies substantially influence net revenue potential.
FAQs
Q1: How soon will biosimilars significantly impact the market pricing for rivaroxaban?
Biosimilar approvals are not yet secured for rivaroxaban. Anticipation exists for biosimilars around 2026-2027, which could precipitate price reductions.
Q2: What factors could accelerate price declines for this drug?
Accelerated biosimilar approvals, patent litigations, and increased generic competition are primary factors.
Q3: How does the pricing of rivaroxaban compare internationally?
In Europe, prices are generally 20-40% lower due to different pricing regulations and negotiated discounts.
Q4: What is the impact of new anticoagulant agents on this market?
Introduction of novel agents with improved safety profiles could alter prescribing patterns and pricing strategies.
Q5: How do payer policies influence net prices for rivaroxaban?
Payer strategies—including formulary restrictions, tiered copays, and negotiations—shape the effective price paid and reimbursement levels.
Citations:
[1] Grand View Research. (2022). Anticoagulants Market Size, Share & Trends.
[2] IQVIA. (2022). U.S. Anticoagulant Market Data Report.
